Compare Baxter International Inc (BAX) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Gitlab Inc — how do they compare? Baxter International Inc trades at $27.23 (market cap $14.27B), while Gitlab Inc trades at $40.9 (market cap $7.11B). The key difference: Baxter International Inc is far larger — about 2× Gitlab Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| BAX | GTLB | |
|---|---|---|
Market Cap | $14.27B | $7.11B |
Sector | Health | Technology |
52-Week High | $28.35 | $51.04 |
52-Week Low | $15.80 | $19.42 |
Enterprise Value | $21.79B | $5.85B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
GitLab (GTLB) trades at $40.98, up 0.61% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Revenue grew to $759.25M in 2025, with a high gross margin of 86.74%, but net income remains negative. Recent news highlights AI-driven product launches and Gartner leadership recognition, fueling positive sentiment.
Outlook: Growth prospects are robust due to AI integration and market position, but high valuation (P/E 521.22) and lack of profitability pose risks. Analyst consensus is mixed with a $32.92 price target, suggesting caution despite operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
